Naoki Tani1, Hideyuki Ikematsu2, Takeyuki Goto1, Kei Gondo3, Takeru Inoue1, Yuki Yanagihara4, Yasuo Kurata4, Ryo Oishi5, Junya Minami5, Kyoko Onozawa5, Sukehisa Nagano6, Hiroyuki Kuwano7, Koichi Akashi1, Nobuyuki Shimono8, Yong Chong1. 1. Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. 2. Ricerca Clinica Co, Fukuoka, Japan. 3. Clinical Laboratory, Fukuoka City Hospital, Fukuoka, Japan. 4. Pharmacy, Fukuoka City Hospital, Fukuoka, Japan. 5. Department of Infectious Diseases, Fukuoka City Hospital, Fukuoka, Japan. 6. Department of Neurology, Fukuoka City Hospital, Fukuoka, Japan. 7. Department of Surgery, Fukuoka City Hospital, Fukuoka, Japan. 8. Center for the Study of Global Infection, Kyushu University Hospital, Fukuoka, Japan.
Abstract
Background: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use. Methods: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2-naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary. Results: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48-6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication. Conclusions: These results suggest an independent correlation between mRNA vaccine-induced specific IgG levels and post-booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers.
Background: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use. Methods: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2-naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary. Results: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48-6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication. Conclusions: These results suggest an independent correlation between mRNA vaccine-induced specific IgG levels and post-booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers.
Authors: Elizabeth P Ryan; Stephen J Pollock; Stephen J Pollack; Thomas I Murant; Steven H Bernstein; Raymond E Felgar; Richard P Phipps Journal: J Immunol Date: 2005-03-01 Impact factor: 5.422
Authors: James N Moy; Mark Anderson; Xiaoying Shen; Jia Fu; Michael Stec; Amy Gosha; Dina Naquiallah; Jennifer Kinslow; David C Montefiori; Gavin Cloherty; Alan Landay Journal: J Infect Dis Date: 2022-10-17 Impact factor: 7.759
Authors: Madhusudhanan Narasimhan; Lenin Mahimainathan; Ellen Araj; Andrew E Clark; John Markantonis; Allen Green; Jing Xu; Jeffrey A SoRelle; Charles Alexis; Kimberly Fankhauser; Hiren Parikh; Kathleen Wilkinson; Annika Reczek; Noa Kopplin; Sruthi Yekkaluri; Jyoti Balani; Abey Thomas; Amit G Singal; Ravi Sarode; Alagarraju Muthukumar Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948
Authors: Maria Elena Romero-Ibarguengoitia; Diego Rivera-Salinas; Yodira Guadalupe Hernández-Ruíz; Ana Gabriela Armendariz-Vázquez; Arnulfo González-Cantú; Irene Antonieta Barco-Flores; Rosalinda González-Facio; Laura Patricia Montelongo-Cruz; Gerardo Francisco Del Rio-Parra; Mauricio René Garza-Herrera; Jessica Andrea Leal-Meléndez; Miguel Ángel Sanz-Sánchez Journal: PLoS One Date: 2022-03-02 Impact factor: 3.240
Authors: Edson D Moreira; Nicholas Kitchin; Xia Xu; Samuel S Dychter; Stephen Lockhart; Alejandra Gurtman; John L Perez; Cristiano Zerbini; Michael E Dever; Timothy W Jennings; Donald M Brandon; Kevin D Cannon; Michael J Koren; Douglas S Denham; Mezgebe Berhe; David Fitz-Patrick; Laura L Hammitt; Nicola P Klein; Haylene Nell; Georgina Keep; Xingbin Wang; Kenneth Koury; Kena A Swanson; David Cooper; Claire Lu; Özlem Türeci; Eleni Lagkadinou; Dina B Tresnan; Philip R Dormitzer; Uğur Şahin; William C Gruber; Kathrin U Jansen Journal: N Engl J Med Date: 2022-03-23 Impact factor: 91.245
Authors: Pinja Jalkanen; Pekka Kolehmainen; Hanni K Häkkinen; Moona Huttunen; Paula A Tähtinen; Rickard Lundberg; Sari Maljanen; Arttu Reinholm; Sisko Tauriainen; Sari H Pakkanen; Iris Levonen; Arttu Nousiainen; Taru Miller; Hanna Välimaa; Lauri Ivaska; Arja Pasternack; Rauno Naves; Olli Ritvos; Pamela Österlund; Suvi Kuivanen; Teemu Smura; Jussi Hepojoki; Olli Vapalahti; Johanna Lempainen; Laura Kakkola; Anu Kantele; Ilkka Julkunen Journal: Nat Commun Date: 2021-06-28 Impact factor: 14.919